The mutations D188V, V1353L, I1656M in the neuronal gene sodium-channel
alpha1-subunit, SCN1A, are disclosed. The methods of using their
associated polypeptides for treating sodium channel dysfunction disorders
including generalized epilepsy are also disclosed.